Abstract:Objective: To prospectively observe the long-term antiviral efficacy and safety of telbivudine (LDT) administered as a monotherapy and as a combination therapy with adefovir dipivoxil (ADV) in patients diagnosed with chronic hepatitis B (CHB) and positivity for hepatitis B e antigen (HBeAg). Methods: A total of 140 patients with HBeAg-positive CHB were randomly divided into treatment groups for LDT monotherapy (n = 75; 600 mg orally, once daily) and LDT+ADV combination therapy (n = 65; LDT 600 mg plus ADV 10 mg orally, once daily). The shortest treatment course was 96 weeks and the longest was 240 weeks. At treatment weeks 12, 24, 48?, 96, 144, 192, and 240 patients were tested for hepatitis B virus (HBV) DNA, HBeAg seroconversion and ALT normalization time; in addition, the incidence and type of adverse drug reactions were recorded. Data were statistically analyzed to determine the significance of differences observed between groups. Results: The rate of patients experiencing more than or equal to 2 log HBV DNA reduction was higher in the LDT + ADV group (92.3%(60/65) vs. LDT: 86.7%(65/75), X2 = 1.58). The HBV DNA negative rates of the LDT and LDT + ADV groups were 62.7% and 61.5% (X2 = 0.01) at week 24, 76.0% and 81.5% (X2 = 0.63) at week 48, 80.0% and 89.2% (X2 = 2.2) at week 96, 78.3% and 93.3% (X2 = 3.24) at week 144, 83.7% and 91.7% (X2 = 0.47) at week 192, and 93.3% and 88.9% at week 240 (comparison between two groups for each point P more than 0.05); both groups showed higher early and rapid sustained HBV DNA negative rates. For the HBeAg seroconversion, the rates of the LDT and LDT + ADV groups were 17.3% and 23.1% (X2 = 0.71) at week 24, 29.3% and 30.8% (X2 = 0.03) at week 48, 42.7% and 40.0% (X2 = 0.10) at week 96, 55.0% and 43.3% (X2 = 1.08) at week 144, 55.8% and 66.7% (X2 = 0.45) at week 192, and 63.3% and 66.7% at week 240; however, pairwise comparison showed no statistically significant differences between the groups (P more than 0.05). Similarly, there was no significant difference between the two groups in incidence of resistance at week 48 (4.0% and 1.5%), week 96 (5.3% and 3.1%), week 144 (10.0% and 3.3%, X2 = 1.23), week 192 (11.6% and 8.3%), and week 240 (13.3% and 11.1%) (all P more than 0.05). Three patients experienced muscle soreness (LDT, n = 2; LDT + ADV, n = 1) and two patients experienced increased creatine phosphokinase (LDT, n = 1; LDT + ADV, n = 1); all side effects resolved spontaneously or with symptom-appropriate treatment. Conclusion: The long-term efficacy of LDT as a monotherapy or as a combination therapy with ADV was similar and the two different treatment approaches were associated with similar rates of resistance. The long-term safety was good for both treatment approaches.

Effects of telbivudine alone or in combination with interferon on the mitochondria of SH-SY5Y cell lines in vitro

Effect of domestic decitabine influence on morphology, proliferation and CD80 expression in mouse lymphoma/leukemia cell line EL4 cells

Interferon-α in Combination with Homoharringtonine Induces K562 Cell Apoptosis Through Down-Regulating Human Telomerase Reverse Transcriptase Expression and Telomerase Activity

Effects of IFN-α2b on Telomerase Activity and the Toxic Effects to Cultured Choroidai Melanoma of Human Eves

910 A PROSPECTIVE, RANDOMIZED STUDY OF EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A VERSUS ADEFOVIR DIPIVOXIL IN TREATING LAMIVUDINE- RESISTANT HBeAg-POSITIVE CHB

Effect of Telbivudine Therapy on the Cellular Immune Response in Chronic Hepatitis B

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate Versus Emtricitabine and Tenofovir Disoproxil Fumarate As Treatments for Patients with Chronic Hepatitis B

Insights into the mechanisms of telbivudine-induced myopathy associated with mitochondrial dysfunction

[Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients]

Effects of chemotherapeutic drugs on telomer of human liver cancer BEL-7404 cell

Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B.

Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.

Effects of interferon-α and lamivudine therapy on the prognosis of patients with chronic hepatitis B virus infection

P414 ASSESSMENT OF THE CHANGE IN ESTIMATED GLOMERULAR FILTRATION RATES IN TELBIVUDINE- OR LAMIVUDINE-BASED TRERAPY IN PATIENTS WITH CHRONIC HEPATITIS B

Telbivudine Therapy May Shape CD4(+) T-cell Response to Prevent Liver Fibrosis in Patients with Chronic Hepatitis B.

Potential Effects of Telbivudine Versus Entecavir on Renal Function in Patients with Chronic Hepatitis B Virus Receiving Glucocorticoids Therapy.

Motor Development Delay in Offspring is Associated with Prenatal Telbivudine Exposure

Chronic Hepatitis B: A Critical Discussion

Lamivudine/Telbivudine-Associated Neuromyopathy: Neurogenic Damage, Mitochondrial Dysfunction and Mitochondrial Dna Depletion

Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy

Treatment With Telbivudine Positively Regulates Antiviral Immune Profiles In Chinese Patients With Chronic Hepatitis B